A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

被引：0
|
作者：
Chi, K. N.
Beardsley, E. K.
Venner, P. M.
Eigl, B. J.
Hotte, S. J.
Ko, Y.
Saad, F.
Winquist, E.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Juravinski Canc Ctr, Hamilton, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] London Hlth Sci Ctr, London, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5166
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial evaluating concomitant docetaxel and samarium (TAXAM) in patients with hormone refractory metastatic prostate cancer.
    Widmark, A
    Modig, H
    Johansson, M
    Franzen, L
    Johansson, L
    Turesson, I
    Laurell, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 436S - 436S
  • [42] Docetaxel in hormone-refractory metastatic prostate cancer
    Oh, WK
    DRUGS, 2005, 65 (16) : 2296 - 2297
  • [43] A phase II study of paclitaxel and vinorelbine (Pac-Vin) in hormone-refractory metastatic prostate cancer (HRPC): A final update
    Sewak, S.
    Kosmider, S.
    Ganju, V.
    Woollett, A.
    Le, B.
    Yeo, E.
    Henry, M.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Phase II study of topotecan in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Kosierowski, R
    Greenberg, R
    Ramsey, HE
    Fox, SC
    Ozols, RF
    McAleer, CA
    Giantonio, BJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 235 - 240
  • [45] Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.
    Meluch, AA
    Spigel, DS
    Greco, FA
    Barton, JH
    Messina, G
    Gould, B
    Rovito, MA
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 436S - 436S
  • [46] Docetaxel (D) plus estramustine monophosphate (EMP) in patients (pts) with hormone refractory prostate cancer (HRPC).
    Nelius, T
    Reiher, F
    Lindenmeir, T
    Burandt, J
    Rau, O
    Filleur, S
    Klatte, T
    Yap, R
    Allhoff, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 447S - 447S
  • [47] Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy
    Harzstark, A. L.
    Weinberg, V. K.
    Sharib, J.
    Smith, D. C.
    Hussain, M. H.
    Beer, T. M.
    Ryan, C. W.
    Mathew, P.
    Ryan, C. J.
    Small, E. J.
    Rosenberg, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Impact of nail toxicity on survival of patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel
    Scotte, F.
    Banu, E.
    Medioni, J.
    Boudraoui, M.
    Tourani, J. M.
    Banu, A.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)
    Dreicer, R.
    Garcia, J.
    Smith, S.
    Elson, P.
    Triozzi, P.
    Hodnick, S.
    Rini, B.
    Klein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial
    Bouman-Wammes, Esther W.
    van den Berg, H. Pieter
    de Munck, Linda
    Beeker, Aart
    Smorenburg, Carolien H.
    Vervenne, Walter L.
    Coenen, Juleon L. L. M.
    Verheul, Henk M. W.
    Gerritsen, Winald R.
    Van den Eertwegh, Alfons J. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 1 - 9
12345